- The Street Sheet
- Posts
- 💪 Losing Weight In The Wrong Places
💪 Losing Weight In The Wrong Places
Plus, peak burrito season is just around the corner and this company is getting ready.
Happy Wednesday afternoon to everyone on The Street. Here's a snapshot of where markets ended the trading session, plus tomorrow's trade idea delivered to you today.
🟩 | US stocks ended higher Wednesday as Netflix led a broader rally among technology names, pushing the market to new highs.
📈 | One Notable Gainer: Netflix's stock jumped 10.7% following fourth-quarter revenue that surpassed estimates and robust subscriber growth, totaling 260.8 million, exceeding the 256 million predicted.
📉 | One Notable Decliner: DuPont de Nemours' stock dropped 14% following a preannouncement of fourth-quarter results that came in below expectations, with revenue forecasted at $2.90 billion versus the $3 billion analysts anticipated.
💪 | Tomorrow's Trade: Losing Weight In The Wrong Places. Scroll down for more.
YESTERDAY’S POLL RESULTS
🟨🟨🟨🟨🟨⬜️ Gerresheimer (GXI-DE)
🟨⬜️⬜️⬜️⬜️⬜️ SKAN Group (SKAN-CH)
🟨⬜️⬜️⬜️⬜️⬜️ Sartorius (SRT-DE)
🟩🟩🟩🟩🟩🟩 Sandoz Group (SDZ-CH)
S&P 500 Heatmap. Credit: Finviz
All stocks on US exchanges. Credit: Finviz
Global ADR snapshot. Credit: Finviz
MARKET MOVERS
SPOT: Spotify's stock gained 2% after announcing an update to its iPhone app in Europe, allowing in-app purchases of subscriptions and audiobooks.
SAP: SAP's stock rose over 6% as the company announced plans for voluntary buyouts or job changes for 8,000 employees in a major restructuring effort.
AMD: Advanced Micro Devices' stock rose 5.8% following an upgrade to buy from New Street Research, which views AMD as a top choice for data center AI chips, especially if its projected $400 billion market by 2027 materializes.
ASML-NL: ASML's semiconductor equipment stock soared over 9% after its fourth-quarter results exceeded Wall Street forecasts, with a notable 12.5% year-over-year increase in net sales.
T: AT&T's stock declined 3% despite surpassing revenue expectations and gaining more subscribers than anticipated, as the company projected lower-than-expected adjusted earnings for 2024.
TOGETHER WITH COMPOUND REAL ESTATE BONDS
We’ve reversed engineered the traditional barriers to investing so growing your nest egg is easier and accessible to everyone. We’ve unlocked this by making the most prominent alternative asset class more accessible: Real Estate.
What was previously reserved for the top 1% is now delivered in a simple, smart, transparent app.
OVERHEARD ON THE STREET
YF: Nvidia, Microsoft, Google, and other companies will be collaborating with the US government on an AI research program.
Reuters: Chipotle is planning to recruit 19,000 workers for its peak "burrito season" from March to May, surpassing its 2023 hiring target of 15,000 for the same period.
Bloomberg: In 2023, Apple's iPhone overtook Samsung as the top-selling smartphone globally for the first time since 2010, as Apple shipped around 235 million units.
Axios: Ford recalled about 1.89 million Explorer SUVs due to trim detachment risks, posing a safety hazard to other vehicles.
CNN: Microsoft reached a $3 trillion valuation, propelled by the artificial intelligence boom, becoming the second company ever to achieve this milestone.
TOMORROW’S TRADE IDEA, TODAY
Not Exactly The Outcome They Wanted
New weight loss drugs have exploded in popularity recently, and it's no surprise considering how effective they’ve proven to be. ICYMI: We profiled some undercover anti-obesity stocks yesterday.
The one drawback? Many patients are finding they’re not just losing fat — they’re losing muscle as well. That could be a problem, especially for older patients, and lead to increased injuries. It could also slow metabolisms and result in patients regaining the weight they lost.
Combining Medications
There are a few things patients can do to combat muscle loss. This includes weight training and, for better or worse, taking other drugs.
The makers of these weight-loss drugs are aware of the muscle-loss problem as well.
That's why Eli Lilly (LLY) spent almost $2 billion on Versanis, a drug startup aimed at solving the muscle loss issue.
Giving Old Research New Meaning
Researchers have long been developing muscle-loss prevention drugs in an effort to treat diseases that cause atrophy. Nowadays, however, the popularity of these weight-loss drugs has given the research new meaning.
According to analysts, minimizing side effects will be the key to moving forward. Approximately half of the US adult population is eligible for these drugs, so the market for them is massive.
The goal now is to prove to consumers that weight loss through these drugs is possible without muscle loss.
Are you bullish or bearish on Eli Lilly (LLY)? |
TOGETHER WITH COMPOUND REAL ESTATE BONDS
Compound Real Estate saw that the everyday person did not have access to invest like the Wolves on Wall Street do. They were faced with red tape and had to go through a complex and inefficient process, riddled with high fees and outdated middlemen.
They did not have the time, knowledge, or stability to invest in the convoluted, high volatility market.
They set out to change that. We decided to level the playing field by unlocking access to the largest alternative investment category: real estate.
ON OUR RADAR
CNBC: China's 2023 imports of integrated circuits dropped 15.4% year-on-year to $349.4 billion, influenced by U.S. restrictions, as per customs data.
MW: Delinquencies in the commercial real estate debt market are rising due to overdue office loans, with a 6.5% delinquency rate in the fourth quarter.
WSJ: The average percentage of life spent in good health dropped to 83.6% in 2021, a decrease from 85.8% in 1990.
MW: U.S. mortgage demand increased 10% as the 30-year mortgage rate dropped to its lowest in three weeks.
Axios: Seasonally adjusted Census Bureau data reveals a 3% decline in new business applications in Florida from December 2022 to December 2023, a key indicator of economic sentiment as fewer people start companies in anticipated tough times.
Reply